OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?	56
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy	39
Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis	33
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	30
Treatments and challenges in advanced prostate cancer	27
Role of PSMA PET/CT in imaging and management of prostate cancer	26
Collecting information from all sarcoma reference cancer centres worldwide: achievement and next steps	26
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies	24
Editorial introductions	24
First and further-line multidisciplinary treatment of retroperitoneal sarcomas	23
Epigenetic dynamics of aging and cancer development: current concepts from studies mapping aging and cancer epigenomes	21
The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies	19
Neurorehabilitation in brain tumours: evidences and suggestions for spreading of knowledge and research implementation	17
Psycho-oncology interventions focusing on fatigue and sleep disturbances	17
Harnessing dendritic cells for innovative therapeutic cancer vaccines	17
Safety of assisted reproductive techniques in gynecological cancer patients	16
New hopes in relapsed refractory primary central nervous system lymphoma	16
Editorial introductions	16
Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?	16
Editorial introductions	16
Neoadjuvant and adjuvant approaches in gastroesophageal cancers	15
Impact of sentinel node use in lymphedema formation among gynecologic cancer patients	15
Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers	14
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies	14
How to prevent human papillomavirus-related oropharyngeal cancer?	14

Beyond ‘the good, the bad and the ugly’: let us put rectal cancer patients at the centre of the decision making	14
Indications and technique of minimally invasive surgery in early-stage cervical cancer	13
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	12
The evolving landscape of bispecific antibodies in the treatment of lung cancer	12
Biomarkers and immunotherapy: where are we?	12
Open questions on vorasidenib	12
Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma	12
Editorial introductions	12
Enhancing proactive life-sustaining treatment preference documentation in advanced cancer care: barriers and recommendations	12
Pregnancy-related hormonal changes and thyroid growth: do they have an impact on the higher incidence of differentiated thyroid cancer in women?	11
Editorial introductions	11
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?	11
Recent advances in precision medicine for acute myeloid leukemia	11
Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights	11
Dyadic psychosocial interventions for patients with cancer and their caregivers: an update	11
Circulating tumor DNA in breast cancer: a biomarker for patient selection	10
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives	10
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies	10
Liquid biopsy in brain tumors: moving on, slowly	10
Lung cancer screening in never smokers	10
Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials	9
Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors	9
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results	9
Editorial introductions	9
Pathology and new insights in central nervous system lymphomas	9
A new comprehensive and stratified concept for supportive care in cancer patients	8
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations	8
Current role and indications of minimally invasive surgery in gynecologic oncology	8
Desmoid tumors: who, when and how to treat?	8
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients	8
Machine learning applications and challenges in graft-versus-host disease: a scoping review	8
Editorial introductions	8
How to become a Multinational Association of Supportive Care in Cancer-designated center of excellence in supportive care in cancer	8
The role of genetic testing in prostate cancer screening, diagnosis, and treatment	8
Hybrid magnetic resonance and PET imaging for prostate cancer recurrence	8
Application of single-port techniques in endometrial cancer	8
The 5T's of health disparities in multiple myeloma in Latin America	8
Artificial intelligence in lung cancer: from diagnosis to therapy	8
Mind the target: programmed death ligand 1 in oesophagogastric cancers	7
How to support parenting in patients with cancer and co-parents? From research to practice	7
Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)	7
Pathologic diagnosis of lung cancer – recent developments	7
Editorial introductions	7
Potential application of artificial intelligence in cancer therapy	7
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies	7
New therapies for brain metastases: an update	7
Editorial introductions	7
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results	7
Breast surgery after neoadjuvant therapy	7
Editorial introductions	7

The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy	7
Advantages of robotic surgery in obese patients with endometrial cancer	7
Preclinical glioma models in neuro-oncology: enhancing translational research	7
Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification	7
Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer	7
Question prompt lists to improve communication between cancer patients and healthcare professionals	6
When do I ask for a DNA methylation array for primary brain tumor diagnosis?	6
Immunotherapies in non-metastatic gastrointestinal cancers	6
Polyamine metabolism in prostate cancer	6
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer	6
Sarcoma incidence worldwide: regional differences in histology and molecular subtypes	6
Richter transformation: biological insights, diagnostic challenges and emerging therapies	6
Cellular therapies in sarcoma and other solid tumors	6
Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted?	6
Adjuvant and neoadjuvant approaches in pancreatic cancer	6
How to monitor the side effects of treatments in cancer patients	6
Treatment of radiation-associated angiosarcoma	6
Editorial introductions	6
Precision, personalization, and quality of life for patients with lymphoma	6
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers	6
Targeting cancer stem cell pathways for lung cancer therapy	6
HER2-positive breast cancer: cotargeting to overcome treatment resistance	6
Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments	6